Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

Summary

This study is a multicenter, open-label, randomized controlled trial designed to preliminarily evaluate the efficacy and safety of telitacicept in patients with refractory rheumatoid arthritis during a 24-week treatment period followed by a 2-week follow-up period.

Timeline

Start

2026-09-01

Primary completion

2027-12-30

Completion

2028-06-30

Publications

• Results Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006 Sep;54(9):2793-806. doi: 10.1002/art.22025.
• Results Tao Y, Zhang J, Li H, Zhou J, Wu M. Clinical efficacy and safety of telitacicept combined with methotrexate in the treatment of rheumatoid arthritis. Am J Transl Res. 2026 Apr 15;18(4):3220-3229. doi: 10.62347/PKWI2684. eCollection 2026.
• Results Hofman ZLM, Roodenrijs NMT, Nikiphorou E, Kent AL, Nagy G, Welsing PMJ, van Laar JM. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn? Rheumatology (Oxford). 2025 Jan 1;64(1):65-73. doi: 10.1093/rheumatology/keae544.

Drugs

Indications